CEO Tiziana Life Sciences Surges as Exec Buys 1.05M Shares Amid ALS Breakthrough Buzz
CEO El Rifi Ivor’s 1M‑share buy backs the ALS program, signaling confidence in Tiziana’s intranasal foralumab—an insider move that could spark a short‑term rally but hinges on trial success.
3 minutes to read